What is the significance of the dose-response curve in early-phase studies, and how does it inform the selection of the recommended Phase 2/3 dose?

Prepare for the Drug Discovery and Healthcare Systems Test. Access flashcards and multiple-choice questions with hints and explanations. Ace your exam with our comprehensive resources!

The dose-response curve captures how increasing dose translates into a pharmacologic effect, which is essential in early-phase studies. It shows whether there is a clear relationship between dose and response, where the effect begins (minimum effective dose), and whether there is a point at which higher doses no longer yield meaningful additional benefit but may raise safety risks. By examining this curve alongside safety and PK/PD data, researchers identify the dose range that achieves meaningful target engagement or therapeutic effect while staying within acceptable toxicity limits. This informs the recommended Phase 2/3 dose, aiming for exposures that produce good efficacy with an acceptable safety profile rather than simply pushing to the maximum tolerated dose. The curve also helps detect a plateau where increasing dose offers little extra benefit, reinforcing the choice of an optimal, balanced dose.